Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine

Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine

Adenovirus vectored vaccines are a highly effective strategy to induce cellular immune responses which are particularly effective against intracellular pathogens. Recombinant simian adenovirus vectors were developed to circumvent the limitations imposed by the use of human adenoviruses due to widesp...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй
Үндсэн зохиолчид:	Folegatti, P, Bellamy, D, Roberts, R, Powlson, J, Edwards, N, Mair, C, Bowyer, G, Poulton, I, Mitton, C, Green, N, Berrie, E, Lawrie, A, Hill, A, Ewer, K, Hermon-Taylor, J, Gilbert, S
Формат:	Journal article
Хэвлэсэн:	MDPI 2019

Ижил төстэй зүйлс

Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine
-н: Pedro M. Folegatti, зэрэг
Хэвлэсэн: (2019-05-01)

Lyophilization to enable distribution of ChAdOx1 and ChAdOx2 adenovirus-vectored vaccines without refrigeration
-н: Zhang, C, зэрэг
Хэвлэсэн: (2023)

CMV-associated T cell and NK cell terminal differentiation does not impact immunogenicity of ChAdOx1 vaccination
-н: Sharpe, HR, зэрэг
Хэвлэсэн: (2022)

Lyophilization to enable distribution of ChAdOx1 and ChAdOx2 adenovirus-vectored vaccines without refrigeration
-н: Cheng Zhang, зэрэг
Хэвлэсэн: (2023-06-01)

Stability of Chimpanzee Adenovirus Vectored Vaccines (ChAdOx1 and ChAdOx2) in Liquid and Lyophilised Formulations
-н: Adam Berg, зэрэг
Хэвлэсэн: (2021-10-01)

CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination
-н: Hannah R. Sharpe, зэрэг
Хэвлэсэн: (2022-03-01)

Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved influenza a antigens
-н: Antrobus, R, зэрэг
Хэвлэсэн: (2014)

Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens.
-н: Antrobus, R, зэрэг
Хэвлэсэн: (2014)

Immunogenicity Differences of the ChAdOx1 nCoV-19 Vaccine According to Pre-Existing Adenovirus Immunity
-н: Jinnam Kim, зэрэг
Хэвлэсэн: (2023-04-01)

Clinical assessment of ChAdOx1 vectored vaccines against emerging pathogens
-н: Moreira Folegatti, P
Хэвлэсэн: (2021)

Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector.
-н: O'Hara, G, зэрэг
Хэвлэсэн: (2012)

A single dose of ChAdOx1 Chik vaccine induces neutralising antibodies against four chikungunya virus lineages in a phase 1 clinical trial
-н: Folegatti, P, зэрэг
Хэвлэсэн: (2021)

Combined intranasal and intramuscular parainfluenza 5-, simian adenovirus ChAdOx1- and poxvirus MVA-vectored vaccines induce synergistically HIV-1-specific T cells in the mucosa
-н: Ashley C. Beavis, зэрэг
Хэвлэсэн: (2023-07-01)

Safety and immunogenicity of adenovirus and poxvirus vectored vaccines against a Mycobacterium avium complex subspecies
-н: Folegatti, P, зэрэг
Хэвлэсэн: (2021)

Safety and immunogenicity of ChAdOx1 MERS Vaccine Candidate in Healthy Middle Eastern Adults: a dose-escalation, open-label, non-randomised, phase 1b trial
-н: Bosaeed, M, зэрэг
Хэвлэсэн: (2021)

Effect of Prior ChAdOx1 COVID-19 Immunisation on T-Cell Responses to ChAdOx1-HBV
-н: Charlotte Davis, зэрэг
Хэвлэсэн: (2024-06-01)

Differential immunogenicity between HAdV-5 and chimpanzee adenovirus vector ChAdOx1 is independent of fiber and penton RGD loop sequences in mice
-н: Dicks, M, зэрэг
Хэвлэсэн: (2015)

Design, Immunogenicity and Preclinical Efficacy of the ChAdOx1.COVconsv12 Pan-Sarbecovirus T-Cell Vaccine
-н: Edmund G.-T. Wee, зэрэг
Хэвлэсэн: (2024-08-01)

Safety and Immunogenicity of Adenovirus and Poxvirus Vectored Vaccines against a Mycobacterium Avium Complex Subspecies
-н: Pedro M. Folegatti, зэрэг
Хэвлэсэн: (2021-03-01)

Humoral immunogenicity and efficacy of a single dose of ChAdOx1 MERS vaccine candidate in dromedary camels
-н: Alharbi, N, зэрэг
Хэвлэсэн: (2019)

Humoral Immunogenicity and Reactogenicity of the Standard ChAdOx1 nCoV-19 Vaccination in Taiwan
-н: Jer-Hwa Chang, зэрэг
Хэвлэсэн: (2022-02-01)

Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2
-н: Hermosilla, E, зэрэг
Хэвлэсэн: (2022)

Safety and immunogenicity of a replication deficient simian adenoviral vectored chikungunya vaccine: A phase I, first-in-human, dose escalation trial
-н: Folegatti, PM, зэрэг
Хэвлэсэн: (2019)

Association of Reactogenicity with Immunogenicity of the ChAdOx1 nCoV-19 Vaccine in Patients Undergoing Hemodialysis
-н: Ting-Yun Lin, зэрэг
Хэвлэсэн: (2022-08-01)

HBV001: Phase I study evaluating the safety and immunogenicity of the therapeutic vaccine ChAdOx1-HBV
-н: Tamsin Cargill, зэрэг
Хэвлэсэн: (2023-11-01)

Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population
-н: Nawamin Pinpathomrat, зэрэг
Хэвлэсэн: (2022-05-01)

Durability of ChAdOx1 nCov-19 vaccination in people living with HIV
-н: Ogbe, A, зэрэг
Хэвлэсэн: (2022)

Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2
-н: Eduardo Hermosilla, зэрэг
Хэвлэсэн: (2022-03-01)

Immunogenicity and efficacy of Zika virus envelope domain III in DNA, protein, and ChAdOx1 adenoviral-vectored vaccines
-н: López-Camacho, C, зэрэг
Хэвлэсэн: (2020)

Immunogenicity and Efficacy of Zika Virus Envelope Domain III in DNA, Protein, and ChAdOx1 Adenoviral-Vectored Vaccines
-н: César López-Camacho, зэрэг
Хэвлэсэн: (2020-06-01)

Is the ChAdOx1 Vaccine Safe and Immunogenic as Prophylactic Measure Against the Lethal Human-Coronaviruses? A Systematic Review
-н: Andréia Michelle Alves Cunha de Alcântar, зэрэг
Хэвлэсэн: (2023-07-01)

Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV
-н: Ane Ogbe, зэрэг
Хэвлэсэн: (2022-04-01)

Simian adenoviruses as vaccine vectors
-н: Morris, S, зэрэг
Хэвлэсэн: (2016)

Simian adenoviruses as vaccine vectors
-н: Morris, S, зэрэг
Хэвлэсэн: (2016)

Safety and immunogenicity of CoronaVac and ChAdOx1 heterologous prime-boost vaccines in an overweight population in Chiang Mai, Thailand
-н: Kriangkrai Chawansuntati, зэрэг
Хэвлэсэн: (2024-06-01)

Impact of ChAdOx1 or DNA Prime Vaccination on Magnitude, Breadth, and Focus of MVA-Boosted Immunogen-Specific T Cell Responses
-н: Alex Olvera, зэрэг
Хэвлэсэн: (2024-03-01)

Author Correction: Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population
-н: Nawamin Pinpathomrat, зэрэг
Хэвлэсэн: (2022-09-01)

Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured onthe AGE1.CR.pIX Avian Cell Line
-н: Folegatti, P, зэрэг
Хэвлэсэн: (2019)

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
-н: Folegatti, PM, зэрэг
Хэвлэсэн: (2020)

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
-н: Barrett, J, зэрэг
Хэвлэсэн: (2020)